RA Capital Management’s TherapeuticsMD TXMD Stock Holding History

RA Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-156,250	Closed	-$9.3M	–	105
2021 Q2	$9.3M	Hold	156,250	–	–	0.15%	77
2021 Q1	$10.5M	Hold	156,250	–	–	0.16%	69
2020 Q4	$9.45M	Buy	+156,250	New	+$10.7M	0.13%	70
2015 Q4	–	Sell	-30,369	Closed	-$8.9M	–	45
2015 Q3	$8.9M	Sell	30,369 -3,239	-10%	-$1.15M	1.28%	23
2015 Q2	$13.2M	Hold	33,608	–	–	1.33%	26
2015 Q1	$10.2M	Sell	33,608 -30,615	-48%	-$7.47M	1.01%	23
2014 Q4	$14.3M	Sell	64,223 -4,864	-7%	-$1M	1.54%	20
2014 Q3	$16M	Sell	69,087 -16,974	-20%	-$4.28M	1.89%	17
2014 Q2	$19M	Sell	86,061 -110,708	-56%	-$24.6M	1.92%	17
2014 Q1	$62.1M	Sell	196,769 -36,433	-16%	-$11.6M	4.45%	8
2013 Q4	$60.7M	Sell	233,202 -97,371	-29%	-$21.3M	7.08%	4
2013 Q3	$48.4M	Buy	330,573 +105,321	+47%	+$12.7M	5.05%	5
2013 Q2	$34.1M	Buy	+225,252	New	+$30.9M	4.53%	9

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RA Capital Management's TXMD Position: Q3 2021 in Review

RA Capital Management sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 156,250 shares — an estimated $9.3M sold.

RA Capital Management first reported a position in TXMD in Q2 2013 and held it in 13 quarters. The position peaked at $62.1M in Q1 2014. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

RA Capital Management reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
RA Capital Management sold 156,250 TherapeuticsMD shares in Q3 2021, an estimated $9.3M.
RA Capital Management first reported a position in TherapeuticsMD in Q2 2013 and held it in 13 quarters.
RA Capital Management's TherapeuticsMD position peaked at $62.1M in Q1 2014.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.